MDMA-Assisted Therapy for PTSD : MAPS Sponsored Clinical Trials
Matters Arising: MAPS’ Pivotal Phase 3 Trial Advances Scientific Discourse in Nature Medicine
The results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD have sparked scientific discourse: Highly statistically significant results and exceptional outcomes for people living …
Study: MDMA-Assisted Therapy Will Be Cost-Effective in the Treatment of PTSD
A peer-reviewed study published today in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is cost-effective in the treatment of posttraumatic stress disorder (PTSD). It is estimated …
Psychedelic Psychotherapy for the Treatment of Alcohol and Drug Addiction Now Available at Eleusis
This articles discusses the Eleusis drug addiction treatment center and the role of ketamine in helping people overcome addictions. — Pamala Duncan, Lifestyle.com, July 31, 2010. Eleusis, an alternative …
Over 100 Media Articles About Journal of Psychopharmacology Publication
There are multiple media articles about the publication of MAPS’ U.S. MDMA-assisted psychotherapy study for the treatment of post-traumatic stress disorder (PTSD) study in the Journal of Psychopharmacology. …
MAPS Research Specialist Ilsa Jerome Responds to Report that Ecstasy Damages Brain Cells
Below is the article in CBC News, followed by Ilsa Jerome, Ph.D.’s response. Ecstasy may damage brain cells, study finds Originally appearing here. Last Updated: Tuesday, May 18, 2010 | 7:14 PM ET …
U.S. MDMA/PTSD Paper Revised and Resubmitted
U.S. MDMA/PTSD Paper Revised and Resubmitted; Long-Term Follow-Up Study Continues On Sunday May 9, a manuscript about our flagship U.S. MDMA/PTSD pilot study was resubmitted to a peer-reviewed journal …
MAPS Continues Protocol Development and Plann
In Spain, MAPS is in the protocol development stage for a study being conducted by Jose Carlos Bouso, Ph.D., Jordo Riba, Ph.D., and Manel Barbanoj M.D. Weve agreed upon the protocol design with this team …
MAPS Clinical Plan for End-of-Phase 2 Meeting
On Monday, March 22, MAPS received final approval from our Institutional Review Board (IRB) to move forward with our new MDMA/PTSD study. Michael Mithoefer, M.D. and Annie Mithoefer, BSN will conduct this …
Overview of Amphetamine-Type Stimulant Deaths in the UK – Critical Review and Commentary
“Overview of amphetamine-type stimulant deaths in the UK – critical review and commentary.” By Ilsa Jerome, Ph.D. Despite news generated by a new study authored by Schifano and colleagues, …
MAPS MDMA Supply Analyzed for Quality
MAPS MDMA Supply Analyzed for Quality MAPS currently owns approximately 17 grams of MDMA. We are having the supply of MDMA reexamined for quality assurance. The analysis is intended to make sure that the …
Several MDMA/PTSD Protocol Documents Revised
Several MDMA/PTSD Protocol Documents Revised In light of the results from our US MDMA/PTSD pilot study and preliminary results from our Swiss and Israeli pilot studies, we have completed an overall review …